Form 4: Zivo Bioscience Director Boosts Stake, Corrects Filing

Zivo Bioscience Director Christopher D. Maggiore acquired 23,682 shares of common stock and corrected a previous administrative error in his beneficial ownership.

Summary

• Christopher D. Maggiore, a Director and 10% Owner of Zivo Bioscience, Inc., acquired 23,682 shares of common stock.
• The transaction occurred on October 8, 2025, at a price of $12.01 per share.
• Following this transaction, Maggiore beneficially owns 517,526 shares of Zivo Bioscience common stock.
• The filing also corrects an administrative error from a previous report, which had overstated Maggiore's aggregate beneficial ownership by 13,156 shares.
• The transaction was made pursuant to a Rule 10b5-1 plan.

Sentiment

Score: 8

Explanation: The purchase of shares by a director and 10% owner, Christopher D. Maggiore, indicates strong confidence in the company's future prospects. The correction of a previous administrative error, while noting a past inaccuracy, demonstrates a commitment to accurate reporting.

Positives

• A Director and 10% owner, Christopher D. Maggiore, increased his stake in Zivo Bioscience by acquiring 23,682 shares, indicating confidence in the company.
• The purchase was made at $12.01 per share, reflecting a specific valuation.
• The correction of a previous administrative error demonstrates a commitment to accurate reporting.

Negatives

• An administrative error in a previous filing led to an overstatement of beneficial ownership by 13,156 shares, which required correction.

Risks

• Potential for administrative errors in SEC filings, as evidenced by the correction of an overstated beneficial ownership by 13,156 shares, which could impact investor confidence in reporting accuracy.

Future Outlook

NA

Industry Context

This insider transaction, a purchase by a director and significant shareholder, typically signals management's confidence in the company's future prospects, which can be a positive indicator for investors within the biotech or health sciences industry where Zivo Bioscience operates.

Related Party Transactions

• Christopher D. Maggiore, a Director and 10% Owner, acquired 23,682 shares of common stock from Zivo Bioscience, Inc. at $12.01 per share.

Stakeholder Impact

• Shareholders: Increased confidence due to insider buying; improved transparency with correction of beneficial ownership.

Key Dates

Recommendation

The acquisition of 23,682 shares by Christopher D. Maggiore, a Director and 10% owner, at $12.01 per share, represents a significant insider purchase. This action typically signals strong confidence in Zivo Bioscience's valuation and future performance. While an administrative error in a prior filing was noted, its correction demonstrates transparency. This substantial insider commitment warrants a 'buy' recommendation for investors.

Keywords

Zivo Bioscience, ZIVO, insider trading, Form 4, stock purchase, director ownership, 10b5-1 plan, beneficial ownership